[1] |
International Agency for Research on Cancer,World Health Organization.GLOBOCAN 2012:estimated cancer incidence,mortality and prevalence worldwide in 2012[EB/OL].[ 2018- 03- 05]. Accessed 8 Sept 2016.
|
[2] |
Chen W, Zheng R, Baade PD , et al. Cancer statistics in China,2015[J]. CA Cancer J Clin, 2016,66(2):115-132.DOI: 10.3322/caac.21338.
doi: 10.3322/caac.21338
|
[3] |
Van Cutsem E, Cervantes A, Adam R , et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer[J]. Ann Oncol, 2016,27(8):1386-1422.DOI: 10.1093/annonc/mdw235.
doi: 10.1093/annonc/mdw235
pmid: 27380959
|
[4] |
Oken MM, Creech RH, Tormey DC , et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group[J]. Am J Clin Oncol, 1982,5(6):649-656.DOI: 10.1097/00000421-198212000-00014.
doi: 10.1097/00000421-198212000-00014
|
[5] |
CTCAE v4.0,Common Terminology Criteria for adverse events[EB/OL].( 2010- 06- 14)[2018-03-05]. .
|
[6] |
Roviello G, Ravelli A, Fiaschi AI , et al. Apatinib for the treatment of gastric cancer[J]. Expert Rev Gastroenterol Hepatol, 2016,10(8):887-892.DOI: 10.1080/17474124.2016.1209407.
doi: 10.1080/17474124.2016.1209407
|
[7] |
Rahimi N . Vascular endothelial growth factor receptors:molecular mechanisms of activation and therapeutic potentials[J]. Exp Eye Res, 2006,83(5):1005-1016.DOI: 10.1016/j.exer.2006.03.019.
doi: 10.1016/j.exer.2006.03.019
pmid: 16713597
|
[8] |
Zeng DX, Wang CG, Lei W , et al. Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma[J]. Oncotarget, 2017,8(39):66248-66253.DOI: 10.18632/oncotarget.19908.
doi: 10.18632/oncotarget.19908
pmid: 29029508
|
[9] |
Hu X, Cao J, Hu W , et al. Multicenter phase Ⅱ study of apatinib in non-triple-negative metastatic breast cancer[J]. BMC Cancer, 2014,7(14):820.DOI: 10.1186/1471-2407-14-820.
doi: 10.1186/1471-2407-14-820
pmid: 25376790
|
[10] |
Qin SK . Apatinib in Chinese patients with advanced hepatocellular carcinoma:a phase Ⅱ randomized,open-label trial[J]. J Clin Oncol, 2014,32(15):4019.DOI: 10.1200/jco.2014.32.15_suppl.4019.
doi: 10.1200/jco.2014.32.15_suppl.4019
|
[11] |
许翠洋, 燕飞虎, 唐洁冰 , 等. 阿帕替尼治疗晚期结直肠癌的临床试验观察[J]. 哈尔滨医科大学学报, 2017,51(3):250-253.DOI: 10.3969/j.issn.1000-1905.2017.03.015.
doi: 10.3969/j.issn.1000-1905.2017.03.015
|
[12] |
孙培培, 张龙, 张泰 , 等. 单药阿帕替尼治疗二线及二线以上化疗失败的晚期大肠癌患者疗效分析[J]. 临床肿瘤学杂志, 2017,22(7):646-649.DOI: 10.3969/j.issn.1009-0460.2017.07.015.
doi: 10.3969/j.issn.1009-0460.2017.07.015
|
[13] |
Li J, Qin S, Xu J , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer:results from a randomized,placebo-controlled,parallel-arm,phase Ⅱ trial[J]. J Clin Oncol, 2013,31(26):3219-3225.DOI: 10.1200/JCO.2013.48.8585.
doi: 10.1200/JCO.2013.48.8585
pmid: 23918952
|
[14] |
Grothey A, Cutsem EV, Sobrero A , et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer(CORRECT):an international,multicentre,randomised,placebo-controlled,phase 3 trial[J]. Lancet, 2013,381(9863):303-312.DOI: 10.1016/s0140-6736(12)61900-x.
doi: 10.1016/s0140-6736(12)61900-x
|
[15] |
Li J, Qin S, Xu R , et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer(CONCUR):a randomised,double-blind,placebo-controlled,phase 3 trial[J]. Lancet Oncol, 2015,16(6):619-629.DOI: 10.1016/s1470-2045(15)70156-7.
doi: 10.1016/s1470-2045(15)70156-7
pmid: 25981818
|
[16] |
Xu RH, Li J, Bai Y , et al. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer:a phase Ib study and a randomized double-blind phase Ⅱ study[J]. J Hematol Oncol, 2017,10(1):22.DOI: 10.1186/s13045-016-0384-9.
doi: 10.1186/s13045-016-0384-9
pmid: 5244709
|
[17] |
Zhang Y, Han C, Li J , et al. Efficacy and safety for apatinib treatment in advanced gastric cancer:a real world study[J]. Sci Rep, 2017,7(1):13208.DOI: 10.1038/s41598-017-13192-8.
doi: 10.1038/s41598-017-13192-8
pmid: 29038432
|
[18] |
Marks EI, Tan C, Zhang J , et al. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy[J]. Cancer Biol Ther, 2015,16(12):1710-1719.DOI: 10.1080/15384047.2015.1113355.
doi: 10.1080/15384047.2015.1113355
pmid: 4847811
|
[19] |
Cheng AL, Kang YK, Lin DY , et al. Sunitinib versus sorafenib in advanced hepatocellular cancer:results of a randomized phase Ⅲ trial[J]. J Clin Oncol, 2013,31(32):4067-4075.DOI: 10.1200/JCO.2012.45.8372.
doi: 10.1200/JCO.2012.45.8372
|
[20] |
Duffaud F, Sleijfer S, Litière S , et al. Hypertension(HTN)as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma.A retrospective study based on European Organisation for Research and Treatment of Cancer(EORTC)62043 and 62072 trials[J]. Eur J Cancer, 2015,51(17):2615-2623.DOI: 10.1016/j.ejca.2015.08.002.
doi: 10.1016/j.ejca.2015.08.002
pmid: 26321011
|